Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ziltivekimab B · 1 trial · 3 indications
Months
| Arm | Type | Description |
|---|---|---|
| Ziltivekimab | EXPERIMENTAL | Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years. |
| Name | Type | Description |
|---|---|---|
| Ziltivekimab B | DRUG | Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
| Ziltivekimab C | DRUG | Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
| Placebo (Ziltivekimab B) | DRUG | Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
| Placebo (Ziltivekimab C) | DRUG | Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
Inclusion Criteria: * Chronic kidney disease defined by one of the below: 1. Estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 15 and below 60 mL/min/1.73 m\^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation) 2. Urinary albumi...
Top 4 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| BridgeBio Pharma, Inc. | BBIO | 2 | PHASE3 | Acoramidis |
| Kiniksa Pharmaceuticals International, plc Class A | KNSA | 1 | PHASE2 | KPL-387 |
| AstraZeneca PLC | AZN | 3 | PHASE1 | AZD1705 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
Ziltivekimab B is an investigational monoclonal antibody developed by Novo Nordisk A/S for cardiovascular risk. It is being studied in people with cardiovascular disease, chronic kidney disease and inflammation. It is a Phase 3 candidate and has not been approved for marketing.
Ziltivekimab B is being developed for cardiovascular risk in patients who also have chronic kidney disease and inflammation. The Phase 3 ZEUS study enrolled adults with these conditions. It is investigational, so it is not yet an approved treatment for any indication.
Ziltivekimab B targets interleukin-6, or IL6. It is an IL6 inhibitor and a monoclonal antibody, meaning it is designed to bind and block the activity of this inflammatory cytokine. Targeting IL6 is intended to reduce the inflammation that accompanies cardiovascular and kidney disease.
Ziltivekimab B is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program studying the drug in cardiovascular risk, chronic kidney disease and inflammation.
Ziltivekimab B is in Phase 3 development. Its Phase 3 trial, ZEUS, has completed. The drug remains investigational and has not been approved by the FDA or any other regulator based on the information available.
Ziltivekimab B has been studied in the Phase 3 ZEUS trial, registered as NCT05021835. ZEUS was a randomized, double-blind, placebo-controlled study that enrolled 6,385 adults aged 18 and older across many countries. It examined ziltivekimab B versus placebo in people with cardiovascular disease, chronic kidney disease and inflammation, and it has completed.